Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients

Carcinogenesis

Volumn 31, Issue 8, 2010, Pages 1387-1391

  Chen, Meng ^a   Gu, Jian ^a   Delclos, George L ^b,c   Killary, Ann M ^a   Fan, Zhen ^a   Hildebrandt, Michelle A T ^a   Chamberlain, Robert M ^a   Grossman, H Barton ^a   Dinney, Colin P ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADULT; AGED; AKT2 GENE; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; FEMALE; FOLLOW UP; GENE; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MUSCLE METASTASIS; OUTCOME ASSESSMENT; PIK3R1 GENE; PRIORITY JOURNAL; PROGNOSIS; RAPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; DNA, NEOPLASM; FEMALE; GENETIC VARIATION; GENOTYPE; GERM-LINE MUTATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 77955390999     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq110     Document Type: Article

References (39)

1. Jemal, A. et al. (2009) Cancer statistics. CA Cancer J. Clin, 59, 225-249.
2. Parekh, D.J. et al. (2006) Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J. Clin. Oncol., 24, 5519-5527.
3. Stenzl, A. et al. (2009) The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol, 55, 815-825.
4. Oosterlinck, W. et al. (2002) Guidelines on bladder cancer. Eur. Urol., 41, 105-112.
5. Abraham, R. et al. (2007) Chromosomal deletions in bladder cancer: shutting down pathways. Front. Biosci., 12, 826-838.
6. Ruggeri, E.M. et al. (2006) Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer, 106, 783-788.
7. Liu, L.Z. et al. (2007) AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res., 67, 6325-6332.
8. Faried, L.S. et al. (2008) Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: a potential biomarker and molecular target therapy. Mol. Carcinog., 47, 446-457.
9. Yang, X. et al. (2006) Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res., 66, 3126-3136.
10. Faried, L.S. et al. (2006) Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol. Rep., 16, 57-63.
11. Hou, G. et al. (2007) An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett., 253, 236-248.
12. Lee, S. et al. (2005) Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol. Oncol., 97, 26-34.
13. Wu, X. et al. (2004) The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int., 93, 143-150.
14. Chen, M. et al. (2009) Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis, 30, 2047-2052.
15. Leibovici, D. et al. (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J. Clin. Oncol., 23, 5746-5756.
16. Yang, H. et al. (2008) Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin. Cancer Res., 14, 2236-2244.
17. Storey, J.D. et al. (2004) Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach. J. R. Stat. Soc. Series B Stat. Methodol., 66, 187-205.
18. Storey, J.D. et al. (2003) Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA, 100, 9440-9445.
19. Storey, J.D. (2002) A direct approach to false discovery rates. J. R. Stat. Soc. Series B Stat. Methodol., 64, 479-498.
20. Habuchi, T. et al. (2005) Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology, 66, 64-74.
21. Mitra, A.P. et al. (2006) Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol., 24, 5552-5564.
22. Gu, J. et al. (2005) Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin. Cancer Res., 11, 1408-1415.
23. Andrew, A.S. et al. (2009) Bladder cancer SNP panel predicts susceptibility and survival. Hum. Genet., 125, 527-539.
24. Karam, J.A. et al. (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol., 8, 128-136.
25. Shariat, S.F. et al. (2008) Nomograms for bladder cancer. Eur. Urol., 54, 41-53.
26. Nicholson, K.M. et al. (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal., 14, 381-395.
27. Bellacosa, A. et al. (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer, 64, 280-285.
28. Cheng, J.Q. et al. (1996) Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA, 93, 3636-3641.
29. Thompson, F.H. et al. (1996) Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Cancer Genet. Cytogenet., 87, 55-62.
30. Hildebrandt, M.A. et al. (2009) Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J. Clin. Oncol., 27, 857-871.
31. Philp, A.J. et al. (2001) The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res., 61, 7426-7429.
32. Sun, M. et al. (2001) Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res., 61, 5985-5991.
33. Benistant, C. et al. (2000) A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene, 19, 5083-5090.
34. Parsons, D.W. et al. (2005) Colorectal cancer: mutations in a signalling pathway. Nature, 436, 792.
35. Subramanian, A. et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA, 102, 15545-50.
36. Vivanco, I. et al. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2, 489-501.
37. Sconce, E.A. et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106, 2329-2333.
38. Wu, X. et al. (2008) Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet. Genomics, 18, 955-965.
39. Zheng, S.L. et al. (2008) Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med., 358, 910-919.